Your fact-checks will appear here
Branch of the National Institutes of Health in the United States
The claim that 300,000 Americans die from drug-related causes in a single year is not supported by U.S. mortality data: recent national counts and provisional reports put annual drug-involved overdose...
U.S. drug overdose deaths have fallen sharply from their 2022 peak: provisional CDC data and multiple news outlets report declines in the mid‑20s percent range for 2024 and continued drops into 2025, ...
From 2016 through 2023, deaths involving synthetic opioids (primarily illicit fentanyl) rose sharply from the low thousands to tens of thousands: official counts show synthetic‑opioid deaths of roughl...
Estimates of how many patients prescribed opioids become addicted vary widely by definition and study, but authoritative agencies describe a small-but-consequential risk from prescription exposure and...
Recent, peer-reviewed and federally funded research increasingly finds cannabis can reduce short-term alcohol consumption or cravings in some users, including a multi‑institution NIH‑funded trial that...
Methamphetamine is a powerful central nervous system stimulant that typically raises breathing rate and can cause respiratory symptoms like shortness of breath, but available reporting and reviews als...
There is no reputable source among the provided results that says “95% of people use drugs safely.” Major surveys and global reports show large numbers of people use drugs but also record substantial ...
A mix of clinician-level, system-level and community interventions reduces the chance that a patient prescribed opioids will progress to (OUD): safer prescribing (guidelines, , prescriber education), ...
The past 50 years of marijuana research have followed a jagged trajectory: early prohibition-era constraints gave way to expanding observational studies, mixed clinical findings on therapeutic uses, a...
There is no single outcome when jurisdictions move to legalize or decriminalize drugs: evidence and expert opinion in the sources show clear benefits (reduced arrests, potential fiscal gains, regulate...
From 2016 onward, deaths involving synthetic opioids—primarily illicitly manufactured —rose dramatically and overtook other opioid categories as the dominant cause of opioid-related mortality, with an...
A national “map” of fentanyl deaths exists in several official and research products that visualize synthetic-opioid mortality by jurisdiction, and those maps show fentanyl as the dominant driver of o...
Higher opioid doses and longer prescription durations both raise the risk that a patient will develop opioid use disorder (OUD) or continue using opioids long-term: epidemiologic studies show progress...
In the United States, deaths involving synthetic opioids — overwhelmingly illicit fentanyl and its analogs — numbered roughly 72,776 in 2023, making fentanyl the single largest driver of overdose fata...
Reporting and survey data show many people use drugs without meeting criteria for disorder, even as public attention focuses on overdoses and illicit markets; for example, NSDUH found 58.3% of people ...
Fentanyl and other synthetic-opioid overdoses have become a leading cause of death for young U.S. adults: provisional national data show roughly 105,000–108,000 total drug overdose deaths in 2022 with...
Yes — hundreds to thousands of peer‑reviewed cannabis studies are being published now: advocacy tallies say more than 4,000 cannabis papers appeared in 2025 and PubMed lists “over 57,000” marijuana‑re...
Individual risk factors—genetics, personality traits (impulsivity, poor emotional regulation), early trauma and mental‑health disorders—consistently show up in research as strong contributors to devel...